Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results

Autolus Therapeutics (NASDAQ:AUTL) released its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06, FiscalAI reports. The company had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL net product revenue rose to $45.7 million in Q2 2026, up from $26.2 million in Q1 and $20.9 million a year earlier. Management raised full-year 2026 revenue guidance to $140 million–$150 million.
• Commercial expansion is progressing faster than planned, with more than 80 U.S. authorized treatment centers already active by midyear and approximately 20 U.K. centers expected by year-end. Management said most activated centers have already treated patients and reported strong physician adoption.
• Gross margin improved sharply to 55% from 6% in Q1, driven by higher manufacturing volumes, production at the U.K. Nucleus facility, operating efficiencies, and cost reductions. The company is targeting a 65%–70% gross margin for the mature adult ALL business within roughly 12–18 months.
• Management outlined multiple upcoming clinical catalysts, including longer-term CARLYSLE lupus data and initial AUTO8 amyloidosis data by year-end 2026, BOBCAT progressive multiple sclerosis data in 2027, and potential pediatric ALL and lupus nephritis milestones in 2027–2028.
• Autolus drew an initial $75 million under a Perceptive Advisors credit facility, with up to $250 million potentially available subject to revenue milestones. Combined with cash, marketable securities, and anticipated revenue, management expects runway into Q2 2028, though the financing increases future debt obligations.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock traded down $0.14 during trading hours on Wednesday, hitting $2.19. The company’s stock had a trading volume of 1,350,453 shares, compared to its average volume of 1,731,555. The stock has a market cap of $581.55 million, a price-to-earnings ratio of -2.00 and a beta of 2.07. Autolus Therapeutics has a twelve month low of $1.17 and a twelve month high of $2.43. The firm has a fifty day moving average of $1.61 and a 200-day moving average of $1.55.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the second quarter valued at about $28,000. SmartHarvest Portfolios LLC acquired a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $46,000. Invesco Ltd. boosted its position in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the period. Finally, Federation des caisses Desjardins du Quebec acquired a new stake in Autolus Therapeutics in the 4th quarter valued at approximately $62,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Analysts Set New Price Targets

AUTL has been the topic of a number of analyst reports. Weiss Ratings downgraded Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported a second-quarter loss of $0.15 per share, beating the $0.21-per-share analyst consensus by $0.06. Revenue reached $45.69 million, above estimates of $38.56 million, providing a positive earnings surprise for investors. Autolus Therapeutics earnings report
• Positive Sentiment: The company raised its AUCATZYL guidance and highlighted launch progress, suggesting improving demand and execution for its commercialized cancer therapy. The updated outlook was a key catalyst behind the stronger investor response. Autolus shares rise on Q2 beat and higher AUCATZYL guidance
• Positive Sentiment: Management’s earnings presentation and conference call emphasized business updates and commercial momentum, reinforcing expectations that AUCATZYL could support future revenue growth. Autolus Q2 2026 earnings call transcript
• Neutral Sentiment: A reported short-interest update showed zero shares sold short and a zero-day days-to-cover ratio, indicating no measurable short-position data in the report. The figures do not provide a meaningful explanation for the stock’s move.
• Negative Sentiment: Despite the earnings beat, Autolus remains unprofitable, with a negative net margin and negative return on equity. Continued losses and the need to scale AUCATZYL sales remain important risks for investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.